1. Home
  2. VRTX vs BUD Comparison

VRTX vs BUD Comparison

Compare VRTX & BUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • BUD
  • Stock Information
  • Founded
  • VRTX 1989
  • BUD 1366
  • Country
  • VRTX United States
  • BUD Belgium
  • Employees
  • VRTX N/A
  • BUD N/A
  • Industry
  • VRTX EDP Services
  • BUD Beverages (Production/Distribution)
  • Sector
  • VRTX Technology
  • BUD Consumer Staples
  • Exchange
  • VRTX Nasdaq
  • BUD Nasdaq
  • Market Cap
  • VRTX 104.8B
  • BUD 96.4B
  • IPO Year
  • VRTX 1991
  • BUD N/A
  • Fundamental
  • Price
  • VRTX $484.24
  • BUD $54.01
  • Analyst Decision
  • VRTX Buy
  • BUD Buy
  • Analyst Count
  • VRTX 25
  • BUD 3
  • Target Price
  • VRTX $505.61
  • BUD $64.00
  • AVG Volume (30 Days)
  • VRTX 1.5M
  • BUD 2.0M
  • Earning Date
  • VRTX 02-10-2025
  • BUD 02-26-2025
  • Dividend Yield
  • VRTX N/A
  • BUD 1.20%
  • EPS Growth
  • VRTX N/A
  • BUD 4.16
  • EPS
  • VRTX N/A
  • BUD 3.19
  • Revenue
  • VRTX $11,020,100,000.00
  • BUD $59,400,000,000.00
  • Revenue This Year
  • VRTX $9.62
  • BUD $0.87
  • Revenue Next Year
  • VRTX $9.25
  • BUD $0.68
  • P/E Ratio
  • VRTX N/A
  • BUD $16.30
  • Revenue Growth
  • VRTX 11.66
  • BUD N/A
  • 52 Week Low
  • VRTX $377.85
  • BUD $45.94
  • 52 Week High
  • VRTX $519.88
  • BUD $67.49
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 65.58
  • BUD 72.39
  • Support Level
  • VRTX $451.99
  • BUD $52.47
  • Resistance Level
  • VRTX $469.55
  • BUD $53.69
  • Average True Range (ATR)
  • VRTX 11.70
  • BUD 0.58
  • MACD
  • VRTX 0.97
  • BUD 0.45
  • Stochastic Oscillator
  • VRTX 83.48
  • BUD 95.62

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 it acquired SABMiller.

Share on Social Networks: